MA46778B1 - Composition intranasale comprenant de la bétahistine - Google Patents
Composition intranasale comprenant de la bétahistineInfo
- Publication number
- MA46778B1 MA46778B1 MA46778A MA46778A MA46778B1 MA 46778 B1 MA46778 B1 MA 46778B1 MA 46778 A MA46778 A MA 46778A MA 46778 A MA46778 A MA 46778A MA 46778 B1 MA46778 B1 MA 46778B1
- Authority
- MA
- Morocco
- Prior art keywords
- betahistine
- intranasal composition
- intranasal
- otological
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 | |
| PCT/EP2018/052695 WO2018141922A1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46778A1 MA46778A1 (fr) | 2021-04-30 |
| MA46778B1 true MA46778B1 (fr) | 2022-08-31 |
Family
ID=61187302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46778A MA46778B1 (fr) | 2017-02-02 | 2018-02-02 | Composition intranasale comprenant de la bétahistine |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10456386B2 (https=) |
| EP (2) | EP3474850B1 (https=) |
| JP (3) | JP7714323B2 (https=) |
| KR (1) | KR102653545B1 (https=) |
| CN (2) | CN118356397A (https=) |
| AR (1) | AR111699A1 (https=) |
| AU (1) | AU2018216970B2 (https=) |
| CA (1) | CA3051725A1 (https=) |
| CL (1) | CL2019002145A1 (https=) |
| CO (1) | CO2019008657A2 (https=) |
| DK (2) | DK3698791T3 (https=) |
| EA (1) | EA201991817A1 (https=) |
| ES (2) | ES2969301T3 (https=) |
| FI (1) | FI3698791T3 (https=) |
| HR (2) | HRP20201137T1 (https=) |
| HU (2) | HUE065336T2 (https=) |
| IL (1) | IL268353B2 (https=) |
| LT (2) | LT3698791T (https=) |
| MA (1) | MA46778B1 (https=) |
| MX (1) | MX381932B (https=) |
| MY (1) | MY196333A (https=) |
| NZ (1) | NZ755931A (https=) |
| PH (1) | PH12019501785B1 (https=) |
| PL (2) | PL3474850T3 (https=) |
| PT (2) | PT3474850T (https=) |
| RS (2) | RS60554B1 (https=) |
| SA (1) | SA519402324B1 (https=) |
| SG (1) | SG11201906980YA (https=) |
| SI (2) | SI3474850T1 (https=) |
| TN (1) | TN2019000220A1 (https=) |
| TW (1) | TWI760429B (https=) |
| WO (1) | WO2018141922A1 (https=) |
| ZA (1) | ZA201904955B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| CA3179806A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Nasal spray formulation with moisturizing benefits |
| JP2023523410A (ja) * | 2020-04-22 | 2023-06-05 | サノタイズ リサーチ アンド ディベロップメント コープ． | 上気道感染症を治療するための組成物および方法 |
| WO2026062705A1 (en) | 2024-09-23 | 2026-03-26 | Troikaa Pharmaceuticals Limited | Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (https=) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
| JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
| JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
| JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
| ATE319426T1 (de) | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| JP2007533733A (ja) | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | 食物摂取管理の方法 |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2006025882A2 (en) | 2004-08-25 | 2006-03-09 | The Uab Research Foundation | Absorption enhancers for drug administration |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| WO2007076140A2 (en) * | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| BRPI0821647A2 (pt) * | 2007-12-21 | 2015-06-16 | Schering Plough Healthcare | Realce da fotosestabillização de oximetazolina |
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| CN102046170B (zh) * | 2008-05-27 | 2012-11-28 | 墨尔本大学 | 治疗患有咽鼓管功能障碍的哺乳动物的方法 |
| ES2589915T3 (es) * | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| US10471040B2 (en) * | 2014-10-03 | 2019-11-12 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2018
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 HR HRP20201137TT patent/HRP20201137T1/hr unknown
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en not_active Ceased
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active Active
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es not_active Application Discontinuation
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 MX MX2019008961A patent/MX381932B/es unknown
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 JP JP2019541717A patent/JP7714323B2/ja active Active
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 PH PH1/2019/501785A patent/PH12019501785B1/en unknown
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43828B1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| EP3643723A4 (en) | NEW PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF EYE DISEASES WITH SUCH NEW PEPTIDE AS THE ACTIVE SUBSTANCE | |
| MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| EP3842423A4 (en) | 3-AZABICYCLO [3,1,1] HEPTANE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| EP3539550A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH FLOWER EXTRACT OF LILAC SOIL BAST OR FRACTIONS THEREOF AS AN ACTIVE SUBSTANCE | |
| EP3791869A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH COX2 ACETYLATING AGENT AS THE ACTIVE SUBSTANCE | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| AR109012A1 (es) | Sistema de administración transdérmica que contiene galantamina o sales de esta | |
| BR112020026014A8 (pt) | Derivado de lactama condensado | |
| EP3698801A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES, WITH ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC MEDICINAL PRODUCT AS THE ACTIVE SUBSTANCES | |
| MA50383B1 (fr) | Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| CO2017007691A2 (es) | Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración | |
| EP3991727A4 (en) | Composition for treating degenerative brain diseases, containing 2-pentylfuran as active ingredient | |
| EP3741366A4 (en) | COMPOSITION WITH DUNNION AS AN ACTIVE INGREDIENT TO PREVENT OR RELIEVE HAIR LOSS | |
| EA202190317A1 (ru) | Лекарственный препарат для наружного применения |